Powering clinical decisions in ovarian cancer
Understand risk
23%
of patients were found with detectable ctDNA, all of whom experienced disease progression.1
Detect recurrence earlier
100%
sensitivity and specificity longitudinally vs 43% and 78% respectively for CA-1251,2
Predict treatment response
98%
of patients who experienced an increase in ctDNA did not derive an objective response to treatment (after 2 cycles)3
Identify patients at risk of progression PARPi maintenance
Monitoring with Signatera™ can provide earlier insights into therapeutic response and potentially help guide treatment decisions by:
- Identifying non-responders early
- Escalating imaging when warranted
Monitor your patients with confidence
As part of her ovarian cancer monitoring plan, Anne received Signatera™ testing and CA-125 at regular intervals.
A positive Signatera™ result alerted her oncologist to order a scan, which caught a recurrence early. Now, Anne is receiving Signatera™ to monitor response to her maintenance therapy. Since starting therapy, Anne’s Signatera™ results have been negative, so she can feel more confident about her treatment plan.
Discover more data in ovarian cancer
Post-adjuvant MRD assessment
After completion of adjuvant/definitive therapy, ctDNA was detectable in 23% of patients, all of whom experienced disease progression.¹
Surveillance/maintenance
Longitudinally, ctDNA was detected with 100% sensitivity and specificity, while CA-125 had much lower sensitivity (43%) and specificity (78%).1,2
Treatment response monitoring
Signatera™ can help identify response to immunotherapy as early as 6 weeks into treatment in gynecologic cancers.³*
Tailor ovarian cancer treatment with Natera’s portfolio of genomic tests
Altera™ comprehensive genomic profiling (CGP)
Altera™ looks at tumor biomarkers and genomic changes that may help inform treatment planning and clinical trial discussions.
Empower™ hereditary cancer testing
Empower™ is a germline genetic test that looks for inherited cancer risk genes that may be relevant in gynecologic cancers. It may be considered based on your personal history and family history.
Is Signatera™ for ovarian cancer right for your patients?
1Hou JY, et al. Gynecologic Oncology. 2022;167:334-341.
2Chapman et al. Poster presented at 2021 AACR Annual Meeting.
3Bratman et al. Nature Cancer. 2020;1(9):873-881.
4Toboni M, et al. Gynecologic Oncology. 2026;204:37–43.
Footnotes
*Includes high grade serous ovarian cancer (n=18), endometrial cancer (n=2), and cervical cancer (n=1).